CTNM
NASDAQContineum Therapeutics Inc.
Price$11.56-0.14 (-1.20%)
02:30 PM07:45 PM
News · 26 weeks50-75%
2025-12-282026-06-21
Mix1890d
- Other10(56%)
- SEC Filings5(28%)
- Insider3(17%)
Latest news
25 items- INSIDERChief Scientific Officer Lorrain Daniel S. sold $54,862 worth of shares (4,170 units at $13.16) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 139,372 units (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference on Tuesday, June 9th at 1:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
- PRContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on May 14, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)
- SECSEC Form SCHEDULE 13G filed by Contineum Therapeutics Inc.SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
- PRContineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th at 3:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies f
- PRContineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 2026. The following abstracts are posted on ATS 2026's online itinerary planner for registered users. Title: PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists With Distinct Lung Occupancy Profiles and
- SECSEC Form 10-Q filed by Contineum Therapeutics Inc.10-Q - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- PRContineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development MilestonesContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2026 financial results and affirmed its key clinical development milestones. "We're excited to have recently shared positive topline results from our chronic pain trial," said Carmine Stengone, CEO, Contineum Therapeutics. "We continue to steadily enroll PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF). With a projected cash runway that extends through
- INSIDERChief Scientific Officer Lorrain Daniel S. sold $54,694 worth of shares (4,170 units at $13.12) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 143,542 units (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that the Compensation Committee of its Board of Directors granted inducement awards to two new non-executive employees under the Company's 2026 Employment Inducement Equity Incentive Plan. The awards were granted as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each award consists of a non-qualified stock option to purchase 51,000 shares of Class A common stock and was granted on Apri
- SECSEC Form DEFA14A filed by Contineum Therapeutics Inc.DEFA14A - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECSEC Form DEF 14A filed by Contineum Therapeutics Inc.DEF 14A - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- PRContineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain- The trial achieved its primary endpoint demonstrating favorable safety and tolerability - Encouraging trends observed across multiple exploratory efficacy endpoints including improvements in measures of pain and other functional patient-reported outcomes - Results support further evaluation of PIPE-791 for the potential treatment of chronic pain Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-cl
- SECSEC Form SCHEDULE 13G filed by Contineum Therapeutics Inc.SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
- INSIDERSEC Form 4 filed by Lorrain Daniel S.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment with the Company in accordance with Nasdaq L
- SECSEC Form S-8 filed by Contineum Therapeutics Inc.S-8 - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECSEC Form 424B5 filed by Contineum Therapeutics Inc.424B5 - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECSEC Form 10-K filed by Contineum Therapeutics Inc.10-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- PRContineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones- Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones. "We're off to a strong start in 2026, having recently dosed t
- PRContineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies
CTNM FAQ
6 questionsWhere does CTNM stock trade?
Contineum Therapeutics Inc. (CTNM) is listed on NASDAQ.What sector and industry is CTNM in?
Contineum Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Contineum Therapeutics Inc. go public?
Contineum Therapeutics Inc. (CTNM) completed its IPO in 2024.What are analysts saying about CTNM?
Contineum Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $1400.00 price target on 2026-01-08. Recent price targets range from $1400.00 to $3200.00.What companies are similar to CTNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CTNM side-by-side with any of them on Quantisnow.How can I track CTNM on Quantisnow?
Quantisnow aggregates Contineum Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTNM to receive live email and push alerts on every new disclosure.